News

Below please find our latest press releases.

 

March, 5 2010

Phase III REGION-I Study Shows PEP005 (ingenol mebutate) Gel 0.05%
May Reduce Pre-Cancerous Skin Lesions in Patients with Actinic Keratosis

Data Presented at the 68th Annual Meeting of the American Academy of

Dermatology. Specialty pharmaceutical company LEO Pharma today announced
that findings from a
Phase III study evaluating PEP005 (ingenol mebutate)
Gel 0.05% to treat actinic keratosis
(AK), a common pre-cursor to skin cancer,
were presented at the 68th Annual Meeting
of the American Academy of
Dermatology (AAD) (Scientific Session Poster Discussion: P105).

 

Feburary, 1 2010

LEO Pharma’s PEP005 Meets Primary Endpoint in
Phase III Trial for Pre-Cancerous Skin Condition

LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate)
Gel, the company’s lead candidate for the topical treatment of actinic (solar)
keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of
complete clearance of AK lesions in non-head locations.

 

Jan. 19, 2010

LEO Pharma Officially Launches in the United States
Parsippany, New Jersey,Specialty pharmaceutical company LEO Pharma
today announced that findings from a Phase III study evaluating
PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK),
a common pre-cursor to skin cancer, were presented at the 68th
Annual Meeting of the American Academy of Dermatology (AAD)
(Scientific Session Poster Discussion: P105).

 

October 16, 2010

LEO Pharma Hands US Launch Brief To Hill & Knowlton
By Arun Sandhaman
New York, New York, Denmark’s Leo Pharma has selected Hill & Knowlton
to develop a major disease awareness campaign, ahead of the global launch of a
new drug which treats pre-cancerous skin lesions.